Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VRTX
VERTEX PHARMACEUTICALS INCORPORATED
NASDAQ
$547.65
▲ UP 0.57% (3.13)

KEY STATISTICS

Market Cap$139.05 B
52w High$555.69
52w Low$374.17
Dividend Yield—
Frequency—
P/E28.78
Volume732.55K
Shares Out.253.81M

COMPANY

LEADERSHIP

Reshma Kewalramani
CHIEF EXECUTIVE
Reshma Kewalramani

COMPENSATION 2026

Salary$1,600,000
Stock Awards$15,002,270
Incentive Plan Pay$4,118,640
All Other Comp.$423,351
Total$21,144,261

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 24, 1991
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
6,400

PRICE TARGET

Target High$653.00
Target Low$350.00
Target Median$582.50
Target Consensus$560.21

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$3.41B
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2000-08-24Forward2:1

PRICE

$547.65 ▲ UP 0.57% (+$3.13)
OVERLAYS
$546$548$549$5519:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM547.65

About Vertex Pharmaceuticals Incorporated

https://www.vrtx.com ↗

Vertex Pharmaceuticals develops and markets cystic fibrosis therapies like TRIKAFTA, with a pipeline in clinical trials for various serious diseases, collaborating globally and serving specialty healthcare providers.

INDUSTRY

Biotechnology

A PRODUCT VERTEX PHARMACEUTICALS INCORPORATED IS KNOWN FOR

JOURNAVX™ (suzetrigine)
JOURNAVX™ (suzetrigine)

JOURNAVX™, FDA-approved in January 2025, is a groundbreaking oral, non-opioid pain medication for moderate-to-severe acute pain, marking Vertex’s expansion beyond cystic fibrosis and serving as the foundation for a long-term pain treatment franchise.

COMPETITORS

COMPETITOR
ALNY COMPARE
BMRN COMPARE
CRSP COMPARE
GILD COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
TRIKAFTAKAFTRIO$2.65B $2.57B ▼$2.35B ▼$2.5B ▲
ALYFTREK$247M $380.1M ▲$424.4M ▲$573.6M ▲
Manufactured Product Other$175.8M $237.4M ▲$135.9M ▼$137.1M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$1.98B $2.09B ▲$1.78B ▼$2.06B ▲
NonUS$1.36B $4.08B ▲$1.47B ▼$1.58B ▲
Europe$836.9M $885.9M ▲$950M ▲$977.7M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,162
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.17% · 8.1M
QQQ
0.61% · 5.4M
IHVV.AX
0.20% · 3.4M
SPY
0.21% · 3.1M
JEPI
1.24% · 1.1M
CGGR
2.02% · 945.9K
PVAL
2.83% · 759.3K
SCHG
0.53% · 616.4K
FTCS
2.13% · 313.6K
DFUV
0.57% · 165.3K
WLDC.MI
0.69% · 158.5K
QQQI
0.60% · 158.2K
TQQQ
0.23% · 153.6K
FHLC
1.89% · 122.1K
XDWH.L
1.61% · 120.6K
VETS
7.32% · 100.0K
NULG
1.69% · 95.7K
QYLD
0.62% · 95.0K
XZ
XZME.F
0.49% · 87.2K
LSGR
4.82% · 82.2K
SEAC.DE
0.62% · 81.0K
ZSP.TO
0.21% · 79.0K
BBH
8.53% · 74.0K
NDQ.AX
0.61% · 71.4K
GPIQ
0.68% · 70.3K
PB
PBPH
3.02% · 57.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.37%
HOLDERS
2,343
TOP 12 OF 2,343 · RANKED BY POSITION SIZE
Capital World Investors
26.1M sh · $12.97B
Vanguard Group Inc
24.2M sh · $9.48B
Blackrock, Inc.
24.1M sh · $11.98B
Blackrock Inc.
21.3M sh · $9.99B
Capital Research Global Investors
21.1M sh · $9.43B
State Street Corp
11.9M sh · $5.9B
Invesco Ltd.
8.0M sh · $4B
Jpmorgan Chase & Co
7.0M sh · $3.12B
Blackrock Fund Advisors
6.8M sh · $502.28M
Blackrock Institutional Trust Company, N.A.
6.5M sh · $481.25M
Geode Capital Management, LLC
6.1M sh · $2.73B
Capital International Investors
5.1M sh · $2.29B

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Purchase
2026-04-13
 David Taylor
David Taylor
Sale
2026-01-29
 Lisa McClain
Lisa McClain
Sale (Full)
2025-06-11
 Jefferson Shreve
Jefferson Shreve
Purchase
2025-02-24

INSIDER TRADES

★
DIRECTOR
SACHS BRUCE I
Sale · 6.0K shares
2026-08-27
★
OFFICER: EVP, CHIEF REG. & QUALITY OFF.
Tatsis Ourania
Purchase · 8.3K shares
2026-07-21
★
OFFICER: EVP CHIEF PATIENT & EXT AF OFF
Sachdev Amit
Purchase · 8.3K shares
2026-07-21
★
DIRECTOR
SACHS BRUCE I
Purchase · 99 shares
2026-07-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 6
OVERWEIGHT 5
HOLD 2
UNDERPERFORM 1
SECTOR PERFORM 1
22 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Truist Securities BUY Cantor Fitzgerald OVERWEIGHT TD Cowen BUY Canaccord Genuity HOLD UBS BUY Baird UNDERPERFORM RBC Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
BMY$66.93COMPARE
CVS$96.73COMPARE
SYK$321.10COMPARE
MDT$92.56COMPARE
SNY$44.45COMPARE
MCK$910.70COMPARE
GSK$50.56COMPARE
HCA$417.54COMPARE